CLINICAL TRIALS PROFILE FOR IBRUTINIB
✉ Email this page to a colleague
505(b)(2) Clinical Trials for IBRUTINIB
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT02436707 ↗ | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | Janssen, LP | Phase 2 | 2015-05-05 | The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment. |
| New Combination | NCT02436707 ↗ | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | Karyopharm Therapeutics Inc | Phase 2 | 2015-05-05 | The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment. |
| New Combination | NCT02436707 ↗ | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | Roche Pharma AG | Phase 2 | 2015-05-05 | The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment. |
| New Combination | NCT02436707 ↗ | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | Canadian Cancer Trials Group | Phase 2 | 2015-05-05 | The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment. |
| New Formulation | NCT02841150 ↗ | Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules | Completed | Janssen Research & Development, LLC | Phase 1 | 2016-06-01 | The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for IBRUTINIB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01217749 ↗ | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | Completed | Ohio State University | Phase 1/Phase 2 | 2010-12-01 | The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases |
| NCT01217749 ↗ | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | Completed | Pharmacyclics LLC. | Phase 1/Phase 2 | 2010-12-01 | The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases |
| NCT01236391 ↗ | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | Completed | Janssen Pharmaceuticals | Phase 2 | 2011-02-01 | The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population. |
| NCT01236391 ↗ | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | Completed | Pharmacyclics LLC. | Phase 2 | 2011-02-01 | The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population. |
| NCT01325701 ↗ | Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Completed | Pharmacyclics LLC. | Phase 2 | 2011-05-01 | The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse Large B-cell Lymphoma (DLBCL). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IBRUTINIB
Condition Name
Clinical Trial Locations for IBRUTINIB
Trials by Country
Clinical Trial Progress for IBRUTINIB
Clinical Trial Phase
Clinical Trial Sponsors for IBRUTINIB
Sponsor Name
